Brief: Stoke Therapeutics Anticipates Data In Q1 2024 From Studies Of STK-001 For Treatment Of Dravet Syndrome
08/01/2024 18:11
Jan 8 (Reuters) - Stoke Therapeutics Inc STOK.O :
* STOKE THERAPEUTICS INC - DATA ANTICIPATED IN Q1 2024 FROM
STUDIES OF STK-001 FOR TREATMENT OF DRAVET SYNDROME
* STOKE THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES, ANTICIPATED TO FUND OPERATIONS TO END OF 2025
Source text for Eikon: ID:nBw31KC34a
Further company coverage: STOK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Stoke Therapeutics
See all newsBrief: Stoke Therapeutics Announces Inducement Grants
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
U.S. STOCKS ON THE MOVE-Gold miners, Ross Stores, Stoke Therapeutics